GE HealthCare Technologies Earnings Call Transcripts
Fiscal Year 2026
-
Q1 revenue grew 2.9% year-over-year to $5.1B, with strong global demand but profit pressured by inflation and a supplier recall. Guidance for 2026 EPS and margins was reduced, but sales growth and innovation momentum remain strong.
-
Middle East exposure is under 5%, with strong focus on safety and supply chain resilience. Tariff mitigation and productivity initiatives support stable costs, while new product launches and a record backlog drive 3%-4% growth. Major imaging innovations are set to impact revenue in 2027.
-
The conference highlighted strong execution in a dynamic market, robust innovation with multiple new product launches, and a focus on AI and digital growth. Financial guidance anticipates 3%-4% organic growth in 2026, with new products driving further gains from 2027.
-
The session highlighted a robust innovation pipeline, including major AI-enabled product launches and the Flyrcado radiopharmaceutical, supporting accelerated growth from 2026 onward. Strategic capital allocation, operational optimization, and disciplined M&A underpin a positive midterm financial outlook.
Fiscal Year 2025
-
Delivered strong Q4 and 2025 results with revenue and cash flow above expectations, driven by innovation, robust U.S. and EMEA demand, and new product launches. 2026 guidance calls for 3%-4% organic revenue growth, margin expansion, and continued investment in innovation, with a cautious outlook on China.
-
Management highlighted robust order growth, a near-record backlog, and strong innovation across all business segments. Margin expansion is expected through new product launches, supply chain improvements, and reduced tariff impact. AI and software advancements are driving customer adoption and recurring revenue opportunities.
-
Q3 2025 saw 4% organic revenue growth and 6% orders growth, with strong performance in Imaging, AVS, and PDx. Despite tariff headwinds, margin expansion initiatives and innovation investments support raised EPS guidance and a positive medium-term outlook.
-
Strong growth in imaging and diagnostics is driven by new technologies, expanded reimbursement, and digital transformation. AI integration, new product launches, and a robust backlog position the business for accelerated growth from 2026 onward, despite a flat outlook in China.
-
Robust R&D investment and operational efficiency are driving a strong product pipeline, with major launches set for 2026 and beyond. Despite tariff and China-related headwinds, order growth, margin expansion, and digital innovation support a positive mid-term outlook.
-
Q2 2025 saw solid revenue and order growth, record backlog, and strong execution across all segments. Guidance for 2025 was raised on revenue, margin, EPS, and cash flow, with tariff mitigation and innovation pipeline supporting future growth.
-
Q1 saw strong order and sales growth, with broad-based strength but a continued decline in China impacting overall guidance. Product innovation, especially in PDX and imaging, is driving growth, while tariff mitigation and disciplined capital allocation remain priorities.
-
The meeting reviewed strong 2024 financial results, strategic acquisitions, and continued execution of a precision care strategy. All director nominees and executive compensation were approved, while a shareholder proposal on golden parachutes was rejected. Tariff mitigation and global supply chain flexibility remain key priorities.
-
U.S.-China tariff reductions could provide a $0.40 per share benefit if sustained, but guidance remains unchanged pending further developments. Q1 delivered record order growth, with strong U.S. and European performance, while China is expected to recover in the second half.
-
Q1 2025 delivered strong revenue and profit growth, with record orders and robust U.S. demand, but full-year guidance was lowered due to significant tariff impacts. All segments grew, innovation launches progressed, and a $1B share repurchase was authorized.
-
Management highlighted strong innovation, margin expansion, and successful transition to independence. Imaging and digital solutions, especially AI, drive growth, with China showing early signs of recovery. Major partnerships and new product launches like Flyrcado and photon counting CT support a positive multi-year outlook.
-
A major exclusive partnership with Sutter Health is set to drive $1 billion in growth over seven years, while increased R&D investment supports a robust AI-driven product pipeline. Margin expansion, global market growth, and the launch of Flyrcado position the company for sustained performance.
Fiscal Year 2024
-
Q4 and full year 2024 saw strong orders, record backlog, and margin expansion, with robust U.S. demand and innovation driving growth. 2025 guidance anticipates continued revenue and margin gains, despite China headwinds and tariff impacts.
-
Management confirmed improved midterm growth and margin targets, driven by innovation in diagnostics and robust U.S. demand. Margin expansion outpaced expectations due to productivity and cost initiatives, while new reimbursement rules and product launches like Flyrcado support future growth.
-
Management outlined a strategy focused on innovation, margin expansion, and digital transformation, targeting mid-single-digit revenue growth and high teens to 20%+ EBIT margin by 2028. Key growth drivers include new product launches, SaaS and AI integration, and expanding recurring revenue streams.
-
Q3 2024 saw 1% organic revenue growth, strong U.S. and pharmaceutical diagnostics performance, and robust margin expansion, offset by significant China market headwinds. Guidance for full-year adjusted EBIT margin and EPS was raised, with continued investment in innovation and digital solutions.
-
Imaging and AI integration are driving growth and operational efficiency, with radiopharmaceuticals and SaaS models emerging as key future drivers. China remains volatile but promising, while margin gains are supported by lean initiatives and platform rationalization.
-
Significant innovation and commercial execution have driven margin expansion and growth, despite China-related guidance reductions. Margin and free cash flow improvements are supported by lean initiatives, while AI and PDX businesses offer strong future growth potential.
-
Q2 2024 saw 1% organic revenue growth and 3% orders growth, with strong U.S. performance offsetting significant China headwinds. Full-year revenue guidance was lowered due to China, but margin and EPS guidance were maintained, supported by productivity initiatives and robust product innovation.
-
Operational independence has enabled strong innovation and margin expansion, with robust R&D investment and disciplined pricing driving performance. Growth is expected to accelerate in the second half, supported by new product launches, market normalization in China, and ongoing cost optimization.